Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.63 |
| ▸ | INSR | P06213 | 1/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17792917 | 0.96 | EGFR (0.68) | EGFRALKINSRIGF1RKCNH2 | |
| SCHEMBL17792919 | 0.93 | EGFR (0.67) | EGFRALKINSRIGF1RKCNH2 | |
| SCHEMBL17792889 | 0.90 | EGFR (0.72) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL17792850 | 0.89 | EGFR (0.68) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL17792765 | 0.89 | EGFR (0.68) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL15531748 | 0.88 | EGFR (0.72) | EGFRALKINSRIGF1RKCNH2 | |
| SCHEMBL19424179 | 0.88 | EGFR (0.62) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL17792893 | 0.88 | EGFR (0.73) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL23248556 | 0.86 | EGFR (0.71) | EGFRALKINSRIGF1RKCNH2 | |
| SCHEMBL17196832 | 0.86 | EGFR (0.74) | EGFRALKINSRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283398-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-05 | — | — | US | disclosed |
| US-20170283398-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-05 | — | — | US | disclosed |
| EP-3225619-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016082713-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283398-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | EGFR, ERBB2, IGF1R | EGFR 1/4885ALK 177/4885INSR 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.